文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

比较 、 和非BRCA乳腺癌的预后。

Comparing Prognosis for , , and Non-BRCA Breast Cancer.

作者信息

Antunes Meireles Pedro, Fragoso Sofia, Duarte Teresa, Santos Sidónia, Bexiga Catarina, Nejo Priscila, Luís Ana, Mira Beatriz, Miguel Isália, Rodrigues Paula, Vaz Fátima

机构信息

Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisbon, Portugal.

Molecular Pathobiology Research Unit, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisbon, Portugal.

出版信息

Cancers (Basel). 2023 Dec 3;15(23):5699. doi: 10.3390/cancers15235699.


DOI:10.3390/cancers15235699
PMID:38067403
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10705326/
Abstract

BACKGROUND: Germline pathogenic variants (PV) in and genes, which account for 20% of familial breast cancer (BC) cases, are highly penetrant and are associated with Hereditary Breast/Ovarian Cancer Syndrome. Previous studies, mostly including higher numbers of BC patients, yielded conflicting results regarding BC outcomes. In the Portuguese population, BC is diagnosed more frequently than BC. We aimed to compare clinicopathological characteristics and prognosis between BC patients with and mutations and a control group without germline PV (). Furthermore, we explored the frequency and outcomes of risk-reducing surgeries in -mutated patients. METHODS: Prospective follow-up was proposed for patients with a diagnosed PV. For this study, a matched control group (by age at diagnosis, by decade, and by stage at diagnosis) included BC patients without germline PV. We compared overall survival (OS) and invasive disease-free survival (iDFS) within the three groups, and the use of risk-reducing surgeries among the cohort. RESULTS: For a mean follow-up time of 113.0 months, -wt patients showed longer time to recurrence ( = 0.002) and longer OS ( < 0.001). Among patients with mutations, no statistical differences were found, although patients with BC had longer iDFS and OS. Uptake of risk-reducing surgeries (contralateral prophylactic mastectomy and salpingo-oophorectomy) were negative predictors of invasive disease and death, respectively. CONCLUSIONS: Testing positive for a PV is associated with a higher risk of relapse and death in patients with BC in the Portuguese population. Risk-reducing mastectomy and salpingo-oophorectomy were associated with lower incidence of relapse and longer median iDFS and OS, respectively.

摘要

背景:BRCA1和BRCA2基因中的胚系致病变异(PV)占家族性乳腺癌(BC)病例的20%,具有高度外显率,并与遗传性乳腺癌/卵巢癌综合征相关。先前的研究大多纳入了较多数量的乳腺癌患者,但关于乳腺癌的预后结果却相互矛盾。在葡萄牙人群中,BRCA2乳腺癌的诊断频率高于BRCA1乳腺癌。我们旨在比较携带BRCA1和BRCA2突变的乳腺癌患者与无胚系PV(野生型)的对照组之间的临床病理特征和预后。此外,我们还探讨了BRCA1突变患者进行降低风险手术的频率和结果。 方法:对诊断为BRCA1或BRCA2 PV的患者进行前瞻性随访。在本研究中,匹配的对照组(按诊断年龄、按年代和按诊断阶段)包括无胚系PV的乳腺癌患者。我们比较了三组患者的总生存期(OS)和无侵袭性疾病生存期(iDFS),以及BRCA1队列中降低风险手术的使用情况。 结果:平均随访时间为113.0个月,BRCA1野生型患者的复发时间更长(P = 0.002),总生存期更长(P < 0.001)。在携带BRCA2突变的患者中,未发现统计学差异,尽管BRCA2乳腺癌患者的iDFS和OS更长。接受降低风险手术(对侧预防性乳房切除术和输卵管卵巢切除术)分别是侵袭性疾病和死亡的负性预测因素。 结论:在葡萄牙人群中,BRCA1或BRCA2 PV检测呈阳性与乳腺癌患者更高的复发和死亡风险相关。降低风险的乳房切除术和输卵管卵巢切除术分别与较低的复发率以及较长的中位iDFS和OS相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99ff/10705326/29bab9f6df0f/cancers-15-05699-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99ff/10705326/67949f223a49/cancers-15-05699-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99ff/10705326/720f549be891/cancers-15-05699-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99ff/10705326/29bab9f6df0f/cancers-15-05699-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99ff/10705326/67949f223a49/cancers-15-05699-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99ff/10705326/720f549be891/cancers-15-05699-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99ff/10705326/29bab9f6df0f/cancers-15-05699-g003.jpg

相似文献

[1]
Comparing Prognosis for , , and Non-BRCA Breast Cancer.

Cancers (Basel). 2023-12-3

[2]
Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.

Am J Obstet Gynecol. 2021-11

[3]
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.

Ann Ital Chir. 2019

[4]
Can contralateral prophylactic mastectomy and oophorectomy increase survival in BRCA-related breast cancer? Results from the Italian MUTina study.

Eur J Surg Oncol. 2024-10

[5]
Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.

Acta Oncol. 2018-1

[6]
BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.

Mol Genet Genomic Med. 2019-3

[7]
Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.

Eur J Surg Oncol. 2021-8

[8]
Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).

BMC Cancer. 2019-11-27

[9]
Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in Carriers: A Systematic Review and Meta-Analysis.

Cancers (Basel). 2023-3-6

[10]
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.

Oncologist. 1996

引用本文的文献

[1]
Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study.

Breast Cancer Res Treat. 2025-5-23

[2]
Impact of germline BRCA1/2 mutations on response to neoadjuvant systemic therapy and prognosis in breast cancer: a propensity score matched cohort study.

Breast Cancer Res. 2025-5-22

[3]
Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer.

Biologics. 2025-3-13

[4]
Risk-benefits assessment of tamoxifen or raloxifene as chemoprevention for risk reduction of breast cancer among BRCA1 and BRCA2 carriers: a meta-analysis.

Sci Rep. 2025-2-25

[5]
Prognostic Impact of Multiple Synchronous T1 Breast Cancer.

Cancers (Basel). 2024-11-30

[6]
Benign polymorphisms in the BRCA genes with linkage disequilibrium is associated with cancer characteristics.

Cancer Sci. 2024-12

[7]
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing.

Br J Cancer. 2024-11

本文引用的文献

[1]
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.

N Engl J Med. 2021-2-4

[2]
Which Genes for Hereditary Breast Cancer?

N Engl J Med. 2021-2-4

[3]
A Population-Based Study of Genes Previously Implicated in Breast Cancer.

N Engl J Med. 2021-2-4

[4]
Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer.

Acta Oncol. 2019-8-5

[5]
Selected medical interventions in women with a deleterious mutation: a population-based study in British Columbia.

Curr Oncol. 2019-2-1

[6]
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 2018-9-12

[7]
BRCA mutation in breast cancer patients: Prognostic impact and implications on clinical management.

Breast J. 2018-11

[8]
Breast cancer in the GCC countries: A focus on BRCA1/2 and non-BRCA1/2 genes.

Gene. 2018-5-17

[9]
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.

Hum Mutat. 2018-3-12

[10]
mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway.

Hered Cancer Clin Pract. 2018-1-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索